Macrocyclic Inhibitors of Flaviviridae Viruses
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,062,092 | Macrocyclic Inhibitors of Flaviviridae Viruses In force · High confidence | Cypralis Limited | In force | High confidence | ||
| US 9,642,889 | Macrocyclic Inhibitors of Flaviviridae Viruses In force · Medium confidence | Cypralis Limited | In force | Medium confidence | ||
| US 10,472,392 | Macrocyclic Inhibitors of Flaviviridae Viruses In force · Medium confidence | Cypralis Limited | In force | Medium confidence | ||
| Application 15/094,777 | Macrocyclic Inhibitors of Flaviviridae Viruses Abandoned Abandoned Apr 13, 2017 | Cypralis Limited | Abandoned | Abandoned Apr 13, 2017 |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
1 of these is in force and held by Selcia Limited.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.